Discontinuation of Vioxx.
Kim
Peter S
PS
Reicin
Alise S
AS
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D017277:Drug Approval; D005062:European Union; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D015201:Meta-Analysis as Topic; D009288:Naproxen / Q000009:adverse effects; D013450:Sulfones / Q000009:adverse effects*; D014481:United States
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D009288:Naproxen